Labcorp to Spin-Off Clinical Development Business
Two independent, publicly-traded companies will result upon completion.
Labcorp announced that it will spin-off its Clinical Development business, which will create two independent, publicly-traded companies. Labcorp will comprise its routine and esoteric labs, central and early development research labs, as well as its extensive, advanced global laboratory network. The as-yet-unnamed CRO business will provide Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations.
Over the last four quarters ending June 30, 2022, the Clinical Development business delivered total revenue of $3 billion and grew 8.0% on a CAGR basis from second quarter 2019 to second quarter 2022. The Board of Directors, executive leadership, and company name of the Clinical Development business will be determined and announced in the future as plans for the spin-off continue to progress.
In November 2014, Labcorp announced the acquisition of CRO Covance, providing the basis for its greater clinical development capabilities.
Read the detailed press release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
